亨迪药业 (301211.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	459.0M	453.3M	445.9M	663.0M	514.9M
Cost of Revenue	359.1M	353.1M	317.3M	396.7M	366.2M
Gross Profit	100.0M	100.2M	128.6M	266.4M	148.7M
Operating Expenses
R&D Expense	24.1M	25.2M	32.9M	52.8M	19.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	45.9M	44.9M	39.3M	38.9M	36.6M
Selling & Marketing Expense	19.6M	20.6M	22.9M	24.1M	14.9M
Other Expenses	—	—	—	—	—
Total Operating Expenses	89.0M	86.8M	49.7M	71.0M	10.0M
Cost and Expenses	448.0M	439.9M	367.0M	467.7M	376.3M
Operating Income (EBIT)	39.6M	41.9M	100.9M	205.3M	148.7M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	39.0M	41.3M	100.4M	202.8M	147.4M
Income Tax Expense	5.2M	6.4M	8.9M	26.7M	21.6M
Bottom Line
Net Income	33.8M	34.9M	91.5M	176.1M	125.8M
Earnings from Cont. Ops	33.8M	34.9M	91.5M	176.1M	125.8M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	33.8M	34.9M	91.5M	176.1M	125.8M
Per Share
Basic EPS	CN¥0.08	CN¥0.08	CN¥0.22	CN¥0.61	CN¥0.44
Diluted EPS	CN¥0.08	CN¥0.08	CN¥0.22	CN¥0.61	CN¥0.44
Revenue Per Share	CN¥1.00	CN¥1.04	CN¥1.07	CN¥2.30	CN¥1.80
Shares
Basic Shares Outstanding	460.9M	436.4M	416.1M	288.7M	285.9M
Diluted Shares Outstanding	460.9M	436.4M	416.1M	288.7M	285.9M
Profitability Metrics
EBITDA	—	84.3M	125.2M	225.7M	169.1M
D&A	—	42.5M	24.3M	20.3M	20.4M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026